CUOS 2019: High-Risk Prostate Cancer Debate: Surgery

Toronto, Ontario ( In this debate, Dr. Laurence Klotz presented his view and thought on why radical prostatectomy should be performed in patients with high-risk disease, as opposed to radiotherapy.

CUOS 2019: High-Risk Prostate Cancer Debate: Radiation

Toronto, Ontario ( Dr. Gerard Morton participated in the debate of 'High-risk Prostate Cancer Debate: Radiation vs Surgery" and explained why he believes that radiotherapy should be offered to patients with high-risk prostate cancer.

CUOS 2019: Biopsy of the Small Renal Mass - Still Controversial?

Toronto, Ontario ( Dr. Tony Finelli presented on the topic of biopsy of small renal masses. There are common arguments against the routine use of renal tumor biopsy, made by physicians and patients alike.  Dr. Finelli addressed each one of these comments during his talk.

CUOS 2019: Cytoreductive Nephrectomy: Is There Still a Role for Nephrectomy in Patients with Metastatic RCC?

Toronto, Ontario ( There were an estimated 6600 new cases of kidney cancer in Canada in 2018, with a 1/3 of them presenting with regional or distant metastases. According to the European Association of Urology (EAU) guidelines, there is a weak recommendation to perform cytoreductive nephrectomy in favorable and intermediate risk patients with metastatic renal cell carcinoma (RCC). For patients with oligometastatic disease, the guidelines recommend performing immediate cytoreductive nephrectomy if complete resection could be achieved. The recommendations of the National Comprehensive Cancer Network (NCCN) guidelines are quite similar.

CUOS 2019: Bladder Preservation for Invasive Bladder Cancer: Lessons Learned and Future Perspectives

Toronto, Ontario ( In this discussion, the topic of bladder preservation was presented by Dr. Huddart from the Royal Marsden NHS Foundation Trust in the United Kingdom.

Muscle invasive bladder cancer, after diagnosis using TURBT, is usually treated with radical cystectomy with the option of neoadjuvant chemotherapy before surgery. However, another option is treatment with Radiotherapy with or without chemotherapy (radiosensitizer). These patients are then followed with cystoscopy, which can then lead to either salvage radical cystectomy for residual/recurrent invasive disease, or another TURBT with local treatment for the superficial disease recurrence.

CUOS 2019: High-grade Upper Tract Urothelial Carcinoma – Adjuvant Chemotherapy

Toronto, Ontario ( In this debate, Dr. Rodney H. Breau supported the administration of adjuvant chemotherapy over neoadjuvant chemotherapy in upper tract urothelial carcinoma (UTUC).

Dr. Breau began with two statements that according to him, everyone can agree upon:

CUOS 2019: High-grade Upper Tract Urothelial Carcinoma – Neoadjuvant Chemotherapy

Toronto, Ontario ( Dr. Kala S. Sridhar participated in a debate and supported the use of neoadjuvant chemotherapy instead of adjuvant chemotherapy for high-grade upper tract urothelial carcinoma (UTUC).

UTUC is a rare disease involving the renal pelvis and ureter. High-grade disease is usually treated with radical nephroureterectomy, with a 5-year cancer-specific survival of less than 50% for pT3 disease, 5-10% for pT4 disease, and less than 35% for the pN+ disease. Perioperative chemotherapy plays an important role in the treatment of this high-grade disease.
Page 1 of 4

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.